Last edition
News about Global Pharma
Relonchem Gets MHRA Nod for Exemestane 25 mg Tablets
Exemestane by Relonchem, a subsidiary of Markans Pharma, is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.
Global Pharma | 05/11/2025 | By Dineshwori | 130
Eli Lilly has announced plans to invest USD 3 billion in a new manufacturing facility in Katwijk, the Netherlands, to expand its global capacity for producing oral medicines and strengthen its supply chain network.
Global Pharma | 04/11/2025 | By Dineshwori
Merz Aesthetics Unveils Ergonomically Designed Belotero Syringe for Enhanced Precision and Comfort
The syringe has been engineered to provide greater precision, comfort, and control, enhancing the overall treatment experience for both practitioners and patients. It will first be introduced in Europe before a phased rollout across global markets.
Global Pharma | 04/11/2025 | By Darshana
AIxMed and PathNet Partner to Advance Digital Pathology with AI-Driven Urine Cytology
AIxMed has partnered with PathNet to advance digital pathology through its AIxURO solution, an AI-powered platform designed to enhance the analysis of non-invasive urine cytology samples. The collaboration aims to boost diagnostic accuracy and streamline workflows in bladder cancer detection.
Global Pharma | 04/11/2025 | By Dineshwori | 111
US-based biotechnology company Kaigene has signed an exclusive global licensing agreement with South Korean biopharmaceutical giant Celltrion to develop and commercialise two of its nonclinical-stage antibody assets, KG006 and KG002.
Global Pharma | 04/11/2025 | By Dineshwori | 314
Akeso's Ivonescimab Wins 4th Breakthrough Therapy Nod in China for TNBC
Akeso has secured its fourth Breakthrough Therapy Designation (BTD) in China for Ivonescimab, targeting first-line treatment of triple-negative breast cancer (TNBC). The ongoing Phase III HARMONi-BC1 trial is assessing its safety and efficacy in this hard-to-treat cancer type.
Global Pharma | 03/11/2025 | By Dineshwori
EU Approves KEYTRUDA for PD-L1+ Resectable Head and Neck Cancer
KEYTRUDA monotherapy has been approved for use as a neoadjuvant treatment, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and continued thereafter as maintenance monotherapy.
Global Pharma | 30/10/2025 | By Dineshwori | 100
GSK Raises 2025 Outlook as Cancer and HIV Drug Sales Surge
Despite a significant fall in USA sales of its shingles vaccine, Shingrix, GSK shares climbed to their highest level since May 2024, rising as much as 4.3 per cent. The stock has already advanced about 25 per cent this year.
Global Pharma | 30/10/2025 | By Darshana | 159
Cambridge Isotope Laboratories (CIL), a subsidiary of Japan’s Otsuka Pharmaceutical, has signed a Memorandum of Understanding (MoU) with Hyderabad-based Chemtatva Chiral Solutions (CCS) to establish a new entity — Cambridge Isotope Laboratories Pvt. Ltd. — in Hyderabad, India.
Global Pharma | 29/10/2025 | By Dineshwori | 150
GHIT Fund Announces USD 11.6 Million to Boost R&D for TB, Leishmaniasis and Malaria
The Global Health Innovative Technology (GHIT) Fund, a Japan-based international public-private partnership (PPP), has announced a total investment of approximately USD 11.6 million to support four new research and development (R&D) projects targeting tuberculosis (TB), neglected tropical diseases (NTDs) and malaria.
Global Pharma | 29/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy